Autophagy, an evolutionarily conserved cellular self-digestive process, is associated with different diseases and can be inhibited or induced by a series of agents. In this study, we reported that fangchinoline (FCL), an alkaloid from Stephania tetrandra S. Moore, increased the expression of LC3-II and the formation of GFP-LC3 puncta in non-small cell lung cancer (NSCLC) cells. Numerous yellow puncta were observed in mRFP-EGFP-LC3 stably expressed NSCLC cells under FCL treatment and the FCL-increased expression of LC3-II was not further increased after co-treatment with bafilomycin A1, an autophagy inhibitor, suggesting that FCL inhibits autophagic flux. Results of co-localization of GFP-LC3 with LysoTracker Red or lysosomalassociated membrane protein 1 indicated that FCL inhibits autophagosomes-lysosomes fusion.
Introduction
Autophagy is a dynamic self-digestion process that degrades damaged or unnecessary organelles and proteins in a lysosome-dependent manner. 1 The program of autophagy mainly consists of initiation, elongation, fusion, and degradation processes, which are accurately directed by numerous autophagy-related (ATG) proteins.
2 Under stimulation, the isolated membranes generate in the cytoplasm, 2,3 elongate to form autophagosomes and encircle the degradative cargos through two ubiquitination-like systems, namely, the phosphatidylethanolamine-modied microtubule-associated protein light-chain 3 (LC3-II) system and the ATG12-ATG5-ATG16 system. 2, 3 The autophagosomes then fuse with lysosomes to form autolysosomes and subsequently degrade their cargos, which are dependent on the lysosomal functions. 4 During the program of autophagy, the LC3-II protein is located on the surface of autophagosomes and are degraded aer autophagosome-lysosome fusion. 5 In higher eukaryotes, the expression of LC3-II can be used as a protein marker for assessing the occurrence of autophagy. 5, 6 An increasing numbers of studies suggested that autophagy plays an important role in different diseases, including cancer, neurodegeneration, as well as inammation etc.
1 Thus far, numerous autophagy regulators have been identied by using different methods, 7, 8 such as liensinine, 9 oblongifolin C, 10 and andrographolide 11 have been considered as autophagy inhibitors, whereas isorhynchophylline 12 and corynoxine 13 are autophagy inducers. In previous studies, we have also successfully identied some autophagy inducers, like platycodin D, 14, 15 glycerrhetinic acid, 16, 17 licochalcone A, 18 chelerythrine, 19 and baicalein 20 etc. Fangchinoline (FCL), a bis-benzylisoquinoline alkaloid that isolated from the dried root of Stephania tetrandra S. Moore, presents a wide spectrum of biological activities, such as anticancer, 21 neuroprotection, 22 anti-inammatory, 23 as well as antihyperglycaemic activities 24 etc. In this study, FCL was identied as an autophagy regulator in non-small cell lung cancer (NSCLC) cells. Interesting, the mechanism of FCL-regulated autophagy was through both inhibition and induction of autophagic ux. streptomycin), and 1.5 mg mL À1 puromycin. All cells were grown in a 5% CO 2 incubator at 37 C.
Materials and methods

Reagents
Western blot assay
Aer treatment with the indicated methods, cells were washed with PBS, collected, lysed in a radioimmunoprecipitation lysis buffer containing 1% protease inhibitor cocktail and 1% phenylmethanesulfonyl uoride for 20 min at 4 C, and then centrifuged (14 000g) for 20 min at 4 C. The supernatant fraction was collected as protein and the concentrations of proteins were determined with BCA™ Protein Assay Kit (Pierce, Rockford, IL, USA). Equal amounts of proteins were separated by using sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to a polyvinylidene diuoride membrane. The membranes were blocked in 5% non-fat dried milk in phosphate buffer saline-tween at room temperature for 1 h and then incubated with specic primary antibodies overnight at 4 C. The membranes were incubated with the corresponding secondary antibodies at room temperature for 
Cathepsin activity assay
CTSB and CTSD activities were determined by using commercial assay kits (K140-100 and K143-100, BioVision, Mountain View, CA, USA) in accordance with the manufacturer's instructions. Aer treatment with 5 or 10 mM FCL for 24 h, cells were collected and lysed in chilled cell lysis buffer for 10 min at 4 C.
Cell lysate was then transferred into 96-well plates and mixed with reaction buffer and substrate at 37 C for 1.5 h. Samples were read at 400 nm excitation and 505 nm emission for CTSB activity and at 328 nm excitation and 460 nm emission for CTSD activity. The activities of CTSB and CTSD were normalized with the protein concentration.
AO staining assay
Aer treatment with the 5 or 10 mM FCL for 24 h, the cells were incubated with AO dye (1.5 mg mL À1 ) for 30 min at 37 C. The uorescent cell images were obtained with an IN Cell Analyzer 2000 (GE Healthcare, Little Chalfont, UK). Statistical results were obtained with a ow cytometer (FACS-Canto, BD Bioscience, USA). AO produces red uorescence (emission peak at 650 nm) in acidic or lysosomal compartments and green uo-rescence (emission peak between 530 and 550 nm) in cytosolic and nuclear compartments.
LysoTracker Red staining assay
Aer treatment with the 5 or 10 mM FCL for 24 h, the cells were stained with 50 nM LysoTracker Red for 90 min at 37 C. Aer washing with PBS, a total of 10 000 stained cells were collected and analyzed by using a ow cytometer (FACS-Canto, BD Bioscience, USA).
Isolation of cytoplasmic and nuclear fractions assay
The cytosolic and nuclear fractions were isolated by using a commercial assay kit (Beyotime, Shanghai, China) in accordance with the manufacturer's instructions. Following 10 mM FCL treatment, the cells were collected, washed, and re-suspended in 200 mL of cytoplasmic extraction buffer A on ice for 15 min. A total of 10 mL cytoplasmic extraction buffer B was added in cell lysates with vortex for 1 min followed by subsequent centrifugation at 14 000g for 5 min. The supernatant was the cytoplasmic extract. Before the cell lysates were centrifuged at 14 000g for 10 min, the pellet (containing nuclei) was re-suspended in 50 mL of nuclear extraction buffer with vortex at 4 C for 30 min. The supernatant liquid was the nuclear extract. The concentrations of proteins were determined with BCA™ Protein Assay Kit (Pierce, Rockford, IL, USA). Western blot assay was performed to determine the expression levels of the mentioned proteins.
Quantitative real-time polymerase chain reaction (qPCR) assay
The mRNA expressions of SQSTM1, MAP1LC3B, and UVARG were detected by using qPCR assay. Aer the cells were treated with 10 mM FCL for 3 h, the total RNA was extracted with TRIzol reagent (Invitrogen, Carlsbad, CA). The RNA was then reversetranscribed into the single-stranded cDNA with a SuperScript™ III rst strand cDNA synthesis kit (Toyobo, Japan). qPCR was performed through SYBR Green PCR Master Mix (Life Technologies) on a Stratagene Mx3005P multiplex quantitative PCR system (Agilent Technologies). The primers that used in this study were obtained from Invitrogen Life Technologies (Shanghai, China) and listed in Table 1 .
26-28
siRNA transfection assay
The specic target sequences of TFEB (sense:
were synthesized by GenePharma (Shanghai, China). A549 cells were transfected with specic siRNA of TFEB or scrambled by using Lipofectamine™ 2000 transfection reagent (Invitrogen Corp., Carlsbad, CA, USA) in strict accordance with the manufacturer's instructions. The cells were then incubated with 10 mM FCL for 3 h. The expression levels of the mentioned proteins were determined via Western blot assay, and the formation of GFP-LC3 puncta were detected via immunouorescent staining assay.
Statistical analysis
The mean AE SE was determined for each group. Statistical analysis was performed with one-way analysis of variance of Tukey's test and unpaired t-test. Differences were considered statistically signicant for (*) P < 0.05 and (**) P < 0.01. The "ns" means "no statistical difference".
Results
FCL triggers autophagy in NSCLC cells
Increasing the protein expression of LC3-II is essential for autophagosome formation and usually used as a protein marker for autophagy happen. 5, 6 Therefore, we initially assessed the expression of LC3-II protein under FCL treatment by using Western blot assay. As shown in Fig. 1A and B, FCL increased the protein level of LC3-II in concentration-and timedependent manners in NSCLC A549 and NCI-H1299 cells. FCL also increased the accumulation of LC3-II in HELF cells (Fig. 1A) . Another reliable marker of autophagy is the formation of GFP-LC3 puncta. 29 The cells were transiently transfected with GFP-LC3 plasmid before FCL treatment. As shown in Fig. 1C , FCL increased the accumulation of GFP-LC3 puncta in A549 cells in a concentration-dependent manner. These results indicated that FCL triggers autophagy in NSCLC cells.
FCL inhibited autophagic ux in NSCLC cells
To determine the FCL-increased expression of LC3-II protein and the formation of GFP-LC3 puncta were due to induction or inhibition of autophagy process, the mRFP-EGFP-LC3 stably expressed A549 cells were used. When an agent induces autophagic ux (for example, RAP
29
), more red puncta are observed because of the easy-to-quench GFP and the relatively stable mRFP in acidic environment, such as autolysosomes and lysosomes. Meanwhile, inhibition of autophagosomes-lysosomes fusion and/or lysosomal function (for example, BAF
30
) results in the presentation of both green and red uorescence of most puncta; these puncta show yellow uorescence in the merged images.
29 Similar to the result of BAF, FCL stimulated a large amount of yellow puncta, while RAP induced numerous red puncta in the mRFP-EGFP-LC3 stably expressed A549 cells ( Fig. 2A) . Moreover, the autophagy inducer-stimulated Table 1 The related PCR primers
Gene
Forward Reverse expression of LC3-II protein is further enhanced in combinative treatment with BAF, whereas the autophagy inhibitor-stimulated expression of LC3-II was not further increased by co-treatment with BAF. 5 As shown in Fig. 2B , combinative treatment of FCL with BAF failed to further increase the FCL-induced expression of LC3-II protein in A549 and NCI-H1299 cells, suggesting that FCL inhibits autophagic ux in NSCLC cells.
FCL inhibited autophagosome-lysosome fusion in NSCLC cells
At the late stage of autophagic ux, autophagosomes fuse with lysosomes to generate autolysosomes and then degrade cargos. 4 To determine whether FCL inhibits autophagic ux through blockage of autophagosomes-lysosomes fusion, confocal microscopy assay was used to detect the co-localization of GFP-LC3 and LysoTracker Red, a specic dye for live cell lysosome labeling. 31 As shown in Fig. 3A , similar to the result of BAFtreated cells, a remarkable separation of GFP-LC3 and LysoTracker Red was observed in FCL-exposed A549 cells. Meanwhile, GFP-LC3 was co-localized with LysoTracker Red in RAP-treated cells (Fig. 3A) . The intensity of LysoTracker Red dye can be affected by changing the pH. Thus, the co-localizations of GFP-LC3 and LAMP1, a protein marker of lysosome, 32 were determined through immunouorescent assay to further conrm that FCL blocks autophagosomes-lysosomes fusion. As shown in Fig. 3B , as observed in BAF-exposed cells, FCL-treated cells also presented the separation of GFP-LC3 and LAMP1. Meanwhile, RAP induced the signicant co-localizations of GFP-LC3 and LAMP1 (Fig. 3B) . These ndings suggested that FCL blocks autophagosomes-lysosomes fusion.
FCL inhibited the activities of cathepsins and affected lysosomal pH in NSCLC cells
Dysfunction of lysosome also results in the inhibition of autophagic ux. Cathepsins, such as CTSB and CTSD, are the major lysosomal proteases for degrading the lysosomal cargos and for maintaining lysosomal functions. 33 In this study, we investigated whether FCL affects the expressions of mature CTSB and CTSD through Western blot assay, and results indicate that FCL decreases the expressions of mature CTSB and CTSD in A549 cells in a concentration-dependent manner (Fig. 4A) . Moreover, the uorescent substrate assay was applied to measure the enzymatic activities of CTSB and CTSD in FCL-treated A549 cells. As shown in Fig. 4B , FCL signicantly decreased the enzymatic activities of CTSB and CTSD in a concentration-dependent manner, suggesting that the activities of CTSB and CTSD decreased in FCL-exposed A549 cells. The lysosomal pH is also required for lysosomal function. 34 Therefore, an AO dye, which accumulates in the acidic or lysosomal vesicles and presents red uorescence when excited by blue light, 35 was applied to determine the effect of FCL on lysosomal pH. As shown in Fig. 4C , the red uorescence was reduced in FCL-treated A549 cells. To eliminate the possibility of lowered intensity of red uorescence caused by decreased AO loading, the ratio of red uorescent and green uorescent intensities was studied. Results indicate that FCL remarkably decreased the ratio of red uorescent and green uorescent intensities (Fig. 4D ). In addition, the LysoTracker Red DND-99, another dye that can be used to evaluate the lysosomal pH, 36,37 was further used. As shown in Fig. 4E and F, the uorescence of LysoTracker Red was decreased aer FCL treatment, suggesting that FCL affects the lysosomal pH in A549 cells.
The FCL-promoted nuclear translocation of TFEB partially contributed to FCL-increased autophagosomes formation in NSCLC cells
In addition to inhibition of autophagic degradation, we speculated whether the FCL-increased formation of autophagosomes is also due to the enhancement of autophagic ux. The TFEB, a master gene for autophagy and lysosomal biogenesis, 38 was detected aer treatment with FCL for various time points. As shown in Fig. 5A , FCL induced the downshi in TFEB molecular weight, especially in 3 h FCL treatment, and this phenomenon is associated with TFEB nuclear translocation and then expression of autophagic genes. 38, 39 However, this downshi in TFEB molecular weight was gradually attenuated aer prolonging the FCL treatment. To assess whether FCL promotes the nuclear translocation of TFEB, the cytoplasmic and nuclear fractions were isolated aer 3 h FCL treatment. As shown in Fig. 5B , Western blot assay indicated that FCL remarkably decreased the cytoplasmic TFEB protein level and increased the nuclear TFEB protein level in A549 and NCI-H1299 cells. Moreover, the mRNA levels of the TFEB-target genes, such as SQSTM1, MAP1LC3B, and UVARG, 35 increased under FCL treatment for 3 h (Fig. 5C ). To assess whether the FCL-promoted nuclear translocation of TFEB also contributes to FCLaccumulated autophagosomes, siRNA of TFEB assay was studied. As shown in Fig. 6A and B, knockdown of TFEB partly reversed the FCL-induced expression of LC3-II protein and formation of GFP-LC3 puncta under 3 h of FCL treatment. Results demonstrated that promotion of TFEB nuclear translocation also contributes to FCL-increased autophagosome accumulation.
Discussion
Previous study indicated that FCL induces autophagy via the p53/sestrin2/AMPK pathway in hepatocellular carcinoma HepG2 and PLC/PRF/5 cells. 40 We reported that FCL-regulated autophagy (inhibition or induction of autophagy) in NSCLC cells depends on the treatment time of FCL. TFEB coordinates the program of autophagy by increasing the expression of autophagic and lysosomal genes, 38 such as SQSTM1, which is essential for binding the degradative cargos with autophagosomes, 41 MAP1LC3B, which promotes the maturation of autophagosome, 42 and UVARG, which interacts with Beclin 1 and initiates autophagy. 43 Some autophagy stimulators, such as starvation, setin, and curcumin, induce autophagy by promoting the nuclear translocation of TFEB. 38, 44, 45 In the early period of FCL treatment of NSCLC cells, the FCL-increased accumulation of autophagosomes was mainly due to the promotion of the nuclear translocation of TFEB and caused the expression of the ATG genes, including SQSTM1, MAP1LC3B, and UVARG. At the late stage of autophagy, the autophagosomes fuse with lysosomes to form autolysosomes and then degradation of cargos in autolysosomes in a lysosome-dependent manner.
1 In the late period of FCL treatment, FCL increased the accumulation of autophagosomes mainly through the inhibition of autophagosomes-lysosomes fusion and dysfunction of lysosomes. Therefore, whether a compound is an autophagy inducer or inhibitor is a complex issue and depends on the treatment time. Thus far, numerous compounds have been identied as autophagy inducers or inhibitors at a specic time point. Whether these autophagy inducers or inhibitors have opposite effects on the regulation of autophagy at other time points remain unclear. Therefore, screening of autophagy inducers or inhibitors by using a real-time monitored method is necessary for further study.
Autophagy is a dynamic program consisting mainly of generation and degradation.
2 Generation can be mediated through TFEB, PI3K, and ATG1 etc., whereas degradation mainly depends on autophagosomes-lysosomes fusion and lysosomal function. 4 Inhibition of autophagy generation or degradation can remarkably inhibit autophagy; however, these two kinds of autophagy inhibition are quite different. 29 When an autophagy inhibitor obstructs generation, the autophagosomes will not be generated and the cargos, for example, the damaged mitochondria, will not be surrounded by autophagosomes and remain exposed in the cytoplasm. 29, 46 By contrast, when an autophagy inhibitor blocks the degradation, the cargos can still be surrounded by autophagosomes. 29 In this study, FCL promoted autophagosomes formation not only by blocking the degradative process of autophagy through inhibition of autophagosomes-lysosomes fusion and lysosomal function, but also by increasing the generative process of autophagy through promotion of TFEB nuclear translocation. Previous studies indicated that the accumulation of autophagosomes could increase the therapeutic effects of anti-cancer drugs. [47] [48] [49] For example, accumulation of autophagosomes via treatment with the autophagy inhibitor chloroquine remarkably increased the anti-cancer effect of vorinostat, a histone deacetylase inhibitor, in the advanced solid tumors. 49 However, the FCL-increased expression of LC3-II was also observed in the normal human embryonic lung broblast cells, suggesting that the phenomenon of FCL-regulated autophagy effect is not specic to cancer cells. Therefore, the side effects of combined treatment of FCL with the anti-cancer drugs should be considered.
In conclusion, we reported that FCL increased the expression of LC3-II protein and the formation of GFP-LC3 puncta by both stimulating the generation of autophagosomes through promotion of TFEB nuclear translocation and blocking the degradation of autophagosomes through inhibition of autophagosomes-lysosomes fusion and lysosomal function. Findings of this study may provide better understanding of agentmediated autophagy. 
